Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis

Abstract

Early DC (MELD < 16) patients with mild-moderate ascites and those with a healthy cellular baseline BM respond better to growth factor therapy. Addition of EPO to G-CSF provides better regenerative response than G-CSF monotherapy.